On knowledge discovery in open medical data on the example of the FDA drug adverse event reporting system for alendronate (Fosamax)

dc.authorscopusid6505872114
dc.authorscopusid55786953000
dc.authorscopusid23396282000
dc.contributor.authorYildirim,P.
dc.contributor.authorEkmekci,I.O.
dc.contributor.authorHolzinger,A.
dc.date.accessioned2024-05-25T12:31:15Z
dc.date.available2024-05-25T12:31:15Z
dc.date.issued2013
dc.departmentOkan Universityen_US
dc.department-tempYildirim P., Department of Computer Engineering, Faculty of Engineering and Architecture, Okan University, Istanbul, Turkey; Ekmekci I.O., Department of Computer Engineering, Faculty of Engineering and Architecture, Okan University, Istanbul, Turkey; Holzinger A., Institute for Medical Informatics, Statistics and Documentation, Medical University Graz, A-8036 Graz, Austriaen_US
dc.description.abstractIn this paper, we present a study to discover hidden patterns in the reports of the public release of the Food and Drug Administration (FDA)'s Adverse Event Reporting System (AERS) for alendronate (fosamax) drug. Alendronate (fosamax) is a widely used medication for the treatment of osteoporosis disease. Osteoporosis is recognised as an important public health problem because of the significant morbidity, mortality and costs of treatment. We consider the importance of alendronate (fosamax) for medical research and explore the relationship between patient demographics information, the adverse event outcomes and drug's adverse events. We analyze the FDA's AERS which cover the period from the third quarter of 2005 through the second quarter of 2012 and create a dataset for association analysis. Both Apriori and Predictive Apriori algorithms are used for implementation which generates rules and the results are interpreted and evaluated. According to the results, some interesting rules and associations are obtained from the dataset. We believe that our results can be useful for medical researchers and decision making at pharmaceutical companies. © 2013 Springer-Verlag.en_US
dc.identifier.citation14
dc.identifier.doi10.1007/978-3-642-39146-0_18
dc.identifier.endpage206en_US
dc.identifier.isbn978-364239145-3
dc.identifier.issn1611-3349
dc.identifier.scopus2-s2.0-84879858848
dc.identifier.scopusqualityQ3
dc.identifier.startpage195en_US
dc.identifier.urihttps://doi.org/10.1007/978-3-642-39146-0_18
dc.identifier.urihttps://hdl.handle.net/20.500.14517/2271
dc.identifier.volume7947 LNCSen_US
dc.language.isoen
dc.relation.ispartofLecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) -- 3rd International Workshop on Human-Computer Interaction and Knowledge Discovery in Complex, Unstructured, Big Data, HCI-KDD 2013, Held at SouthCHI 2013 -- 1 July 2013 through 3 July 2013 -- Maribor -- 97742en_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectalendronate (fosamax)en_US
dc.subjectapriori algorithmen_US
dc.subjectbiomedical data miningen_US
dc.subjectcooccurrence analysisen_US
dc.subjectdrug adverse eventen_US
dc.subjectknowledge discoveryen_US
dc.subjectOpen medical dataen_US
dc.subjectosteoporosisen_US
dc.titleOn knowledge discovery in open medical data on the example of the FDA drug adverse event reporting system for alendronate (Fosamax)en_US
dc.typeConference Objecten_US
dspace.entity.typePublication

Files